Drug intelligence / Profile preview

TRTL-118

Development stage: Preclinical
Lead developer: Tortugas Neuroscience
Modality: Small Molecules

Overview

TRTL-118 is a small molecule phosphodiesterase 9 (PDE9) inhibitor currently in preclinical development by Tortugas Neuroscience. The drug is being investigated for the treatment of reversible encephalopathies, a group of neurological conditions characterized by transient brain dysfunction. PDE9 is an enzyme that specifically hydrolyzes cyclic guanosine monophosphate (cGMP), a critical second messenger involved in synaptic plasticity and neuronal signaling. By inhibiting PDE9, TRTL-118 aims to elevate intracellular cGMP levels, thereby potentially restoring normal neuronal function and addressing the cognitive or neurological deficits associated with encephalopathic states.

Targets

PDE9A (Phosphodiesterase 9A)

Beyond the preview

Go deeper on TRTL-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRTL-118.

Explore the full profile